Related Experiment Video
Updated: Oct 22, 2025

Characterizing RNA Modifications in Single Neurons Using Mass Spectrometry
Published on: April 21, 2022
N6-methyladenosine (m6A) modification and its clinical relevance in cognitive dysfunctions
Bingying Du1, Yanbo Zhang2, Meng Liang1
1Department of Neurology, Shanghai Changhai Hospital, The Second Military Medical University, Shanghai, PR China.
Background:
N6 adenosine methylation (m6A) is the most abundant internal RNA modification in eukaryotic cells. Dysregulation of m6A has been associated with the perturbations of cell proliferation and cell death in different diseases. However, the roles of m6A in the neurodegenerative process and cognitive dysfunction are unclear.
Methods:
We systematically investigated the molecular alterations of m6A regulators and their clinical relevance with cognitive dysfunctions using published datasets of Alzheimer's Disease (AD), vascular dementia, and mild cognitive impairment (MCI).
Findings:
The expressions of m6A regulators vary in different tissues and closely correlate with neurodegenerative pathways. We identified co-expressive m6A regulators SNRPG and SNRPD2 as potential biomarkers to predict transformation from MCI to AD. Moreover, we explored correlations between Apolipoprotein E4 and m6A methylations.
Interpretation:
Collectively, these findings suggest that m6A methylations as potential biomarkers and therapeutic targets for cognitive dysfunction.
Funding:
This work was supported by the National Natural Science Foundation of China (81871040) and the Shanghai Health System Talent Training Program (2018BR29).
Insights
N6 adenosine methylation (m6A) is crucial in cell regulation. This study identifies m6A regulators as potential biomarkers for predicting cognitive decline and Alzheimer's disease progression.
Area of Science:
- Epigenetics and Molecular Biology
- Neuroscience
- Biomarker Discovery
Background:
- N6 adenosine methylation (m6A) is the most prevalent internal RNA modification in eukaryotes.
- m6A dysregulation is linked to cell proliferation and death, but its role in neurodegeneration and cognitive dysfunction remains unclear.
Purpose of the Study:
- To investigate molecular alterations of m6A regulators in neurodegenerative diseases.
- To assess the clinical relevance of m6A regulators in cognitive dysfunction, including Alzheimer's Disease (AD), vascular dementia, and mild cognitive impairment (MCI).
Main Methods:
- Systematic investigation of m6A regulators using published datasets.
- Analysis of gene expression data from AD, vascular dementia, and MCI cohorts.
- Exploration of correlations between Apolipoprotein E4 and m6A methylations.
Main Results:
- m6A regulator expression varies across tissues and correlates with neurodegenerative pathways.
- SNRPG and SNRPD2 identified as co-expressive m6A regulators.
- Potential biomarkers for predicting MCI to AD transformation and links to Apolipoprotein E4 established.
Conclusions:
- m6A methylations show promise as biomarkers for cognitive dysfunction.
- m6A regulators represent potential therapeutic targets for neurodegenerative diseases and cognitive impairment.
Related Concept Videos
RNA Editing
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Biosynthesis of Nucleic Acids
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
RNA Stability
Nuclear Export of mRNA

